<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503149</url>
  </required_header>
  <id_info>
    <org_study_id>ZPM-001</org_study_id>
    <nct_id>NCT03503149</nct_id>
  </id_info>
  <brief_title>Molecular Tumor Board at the Center for Personalized Medicine Tübingen</brief_title>
  <acronym>MTB@ZPM</acronym>
  <official_title>Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular Tumor Board at the Center for Personalized Medicine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Molecular Tumor Board at the Center for Personalized Medicine The study objectives are

        -  To ensure a prospective documentation of all patients who are referred to the Molecular
           Tumor Board in routine clinical care

        -  To prospectively ensure the documentation of MTB patients with an emphasis to clinical
           outcome parameters progression-free survival (PFS), overall survival (OS) and further
           response assessments (e.g. peripheral immunmonitoring, imaging parameters)

        -  To prospectively assess patient-reported outcome of MTB patients

        -  To evaluate compliance to MTB suggestions in routine clinical care
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2028</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>an average of 1 year</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Advanced Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>observational study</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue, blood tisssue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced stages of cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Given informed consent (&quot;broad consent&quot; of the University Hospital Tübingen)

          -  ≥ 18 years of age

          -  Clinical indication for a referral to Molecular Tumor Board by the treating physician

        Exclusion Criteria:

          -  The MTB assists the referring physician with the interpretation and the use of tumor
             molecular profiling data for deciding on a therapeutic strategy. Therefore, this board
             is confined to cancer patients and cannot provide any service for non-cancer patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ghazaleh Tabatabai, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghazaleh Tabatabai, Prof</last_name>
    <phone>0049707129</phone>
    <phone_ext>83269</phone_ext>
    <email>ghazaleh.tabatabai@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nisar P Malek, Prof</last_name>
    <phone>0049707129</phone>
    <phone_ext>83269</phone_ext>
    <email>ghazaleh.tabatabai@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>BW</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghazaleh Tabatabai, Prof</last_name>
      <phone>0049707129</phone>
      <phone_ext>83269</phone_ext>
      <email>ghazaleh.tabatabai@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Nisar P Malek, Prof</last_name>
      <phone>0049707129</phone>
      <phone_ext>83269</phone_ext>
      <email>ghazaleh.tabatabai@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>only within a publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

